{
    "clinical_study": {
        "@rank": "48862", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "3", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether BMS-188667 will decrease multiple\n      sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS\n      exacerbations, compared to placebo"
        }, 
        "brief_title": "A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis", 
        "completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion\n\n          -  relapsing-remitting MS\n\n          -  at least 1 exacerbation in preceding 2 years\n\n          -  at least 1 MRI lesion\n\n          -  stable for 2 months prior to dosing\n\n        Exclusion\n\n          -  progressive MS\n\n          -  currently treated with an immunomodulatory therapy\n\n          -  previously treated with an approved MS drug where treatment was discontinued for lack\n             of efficacy\n\n          -  active bacterial or viral infections"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 3, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035529", 
            "org_study_id": "IM101-200"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "Solution, i.v infusion, 0 mg, Days 1 & 15 then monthly, 10 months.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "Vial, i.v infusion, 2mg/kg, Days 1 & 15 then monthly, 10 months.", 
                "intervention_name": "BMS 188667 (Abatacept)", 
                "intervention_type": "Drug", 
                "other_name": "Orencia"
            }, 
            {
                "arm_group_label": "3", 
                "description": "Vial, i.v infusion, 10 mg/kg, Days 1 & 15 then monthly, 10 months.", 
                "intervention_name": "BMS 188667 (Abatacept)", 
                "intervention_type": "Drug", 
                "other_name": "Orencia"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Abatacept"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "MS", 
        "lastchanged_date": "December 2, 2010", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "Local Institution"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Preliminary efficacy- Reduction in cumulative nr of new or recurrent Gd-enhancing lesions."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035529"
        }, 
        "secondary_outcome": {
            "measure": "Preliminary efficacy: 1) Decrease in annualized relapse rate and 2) Reduction in cumulative nr of new or enlarging T2-weighted MRI lesions."
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2010"
    }, 
    "geocoordinates": {
        "Local Institution": "43.073 -89.401"
    }
}